The corporate venture arm of a pharmaceutical company seeks to make strategic investments into early-stage companies that are aligned with its parent firm’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings. The firm benefits from deep connections into its parent firm’s global research and development centers, and is well placed to nurture innovative pharmaceutical companies and to connect these into the parent organization.
The firm’s core focus is on therapeutics. Currently, the firm is most interested in oncology, gastrointestinal diseases, and CNS. The firm is also interested in breakthrough platforms technologies that improve peptide, antibody, cell, and gene based therapies. The firm does not invest in medical devices or diagnostics.
The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm respects the autonomy of the institutions it invests in and seeks standard institutional venture investment terms without special rights or options.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a Reply